Every 8-K that Enveric Biosciences, Inc. (ENVB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ENVB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENVB filings page.
Enveric Biosciences reported second quarter 2026 results and a business update focused on its lead neuroplastogenic candidate EB-003. The company continued IND-enabling studies, reported additional preclinical data supporting a potential non-hallucinogenic profile, and initiated genotoxicity studies needed for an Investigational New Drug application and a planned Phase 1 trial.
Enveric also expanded its intellectual property, securing a new U.S. patent covering methods of treating psychiatric disorders with EVM301 Series compounds and receiving a Notice of Allowance for a patent on its EVM401 Series of methylone-inspired neuroplastogens. Financially, net loss attributable to stockholders was $3.0 million for the quarter ended June 30, 2026, or $0.76 per basic and diluted share, compared with a net loss of $2.5 million and $11.65 per share a year earlier. Cash-on-hand was $8.3 million as of June 30, 2026, supported by $5.0 million in gross offering proceeds and $1.5 million from warrant exercises during the quarter.
Enveric Biosciences, Inc. filed an 8-K to report that on June 9, 2026 it filed a prospectus supplement to offer an additional $2,425,000 of shares of its common stock under its existing at-the-market equity offering program with H.C. Wainwright & Co., LLC as sales agent. Prior to this date, the company had sold an aggregate of $4,483,711.04 through the sales agent under the same agreement. A legal opinion from Greenberg Traurig, LLP regarding the validity of the shares is included as an exhibit.
Enveric Biosciences, Inc. furnished a Q2 2026 investor presentation under Regulation FD. The company plans to post this Investor Presentation on its website and use it in discussions with current and potential investors, analysts, lenders, business partners, acquisition candidates, customers, and employees.
The Investor Presentation is attached as Exhibit 99.1 and is also accessible via the company’s investor events webpage. The information in this report, including Exhibit 99.1, is furnished rather than filed under the Exchange Act, limiting its treatment under Section 18 and other incorporation-by-reference provisions.
Enveric Biosciences, Inc. reported two main developments. First, the board approved new standard forms of restricted stock unit (RSU) and restricted stock (RSA) award agreements under its 2020 Long-Term Incentive Plan. The RSUs vest over four years, while RSAs vest on specified dates, and both include change in control, forfeiture, and other customary terms for executives and directors.
Second, at the May 28, 2026 annual meeting, 991,828 shares were represented, equal to 52.54% of shares entitled to vote, establishing a quorum. Stockholders elected six directors and approved the advisory say-on-pay proposal with 569,552 votes for and 26,884 against. They extended board authority to implement a reverse stock split within a 1-for-5 to 1-for-15 range (793,344 for, 190,175 against), but voted against increasing authorized common shares to 5,000,000,000 (427,158 for, 555,147 against). The appointment of CBIZ CPAs P.C. as auditor for 2026 was ratified with 960,728 votes for and 19,347 against.
Enveric Biosciences reported first quarter 2026 results and a corporate update centered on its lead neuroplastogenic candidate EB-003 and a strengthened intellectual property portfolio. EB-003 advanced through IND-enabling studies, with new preclinical data showing dual Gq and β-arrestin signaling at 5-HT2A and reduced conditioned fear in a PTSD model.
Net loss attributable to stockholders was $1.6 million, or $1.08 per basic and diluted share, for the quarter ended March 31, 2026, compared with a net loss of $2.2 million, or $14.58 per share, for the same period in 2025. Cash-on-hand was $4.9 million at March 31, 2026, and the company raised $2.8 million in gross proceeds during the quarter.
Subsequent financing events included a private placement of up to $13.9 million priced at-the-market under Nasdaq rules, with $5.0 million received at closing and up to approximately $8.9 million in potential additional warrant proceeds, plus $1.5 million from warrant exercises. As of May 15, 2026, cash was approximately $10.3 million, which management believes will fund EB-003 preclinical completion, an IND filing, and operations into the first quarter of fiscal 2027.
Enveric Biosciences, Inc. filed an 8‑K and supplemental proxy materials to correct a typographical error in its 2026 Annual Meeting proxy. The company confirms that Proposal 3 seeks approval for a reverse stock split in a range of 1‑for‑5 to 1‑for‑15, not 1‑for‑50.
The correction applies to the proxy card and notice of internet availability, while the proposal text already reflected the 1‑for‑15 maximum. The meeting remains scheduled for May 28, 2026 at 10:00 a.m. Eastern Time as a virtual event, and all other proposals and logistics are unchanged.
Enveric Biosciences, Inc. entered into a private placement financing with institutional investors, raising approximately $5.0 million in gross proceeds. The company agreed to sell 2,222,223 shares of common stock, or pre-funded warrants in lieu of shares, together with Series I and short-term Series J warrants, at a purchase price of $2.25 per share (or pre-funded warrant) and accompanying warrants.
The accompanying warrants have an exercise price of $2.00 per share and are exercisable immediately. Series I warrants will expire five years after the effective date of a resale registration statement, while Series J warrants will expire eighteen months after that date. If all Series I and Series J warrants are exercised for cash, Enveric could receive up to an additional $8.9 million in gross proceeds. The company plans to use net proceeds for product development, working capital, and general corporate purposes.
Enveric Biosciences reported a net loss attributable to stockholders of $4.0 million for the quarter ended December 31, 2025, compared with a net loss of $3.2 million a year earlier. Basic and diluted loss per share was $6.12 for the quarter. The company ended 2025 with $4.7 million in cash and raised gross proceeds of $12.2 million during the year through offerings, including $4.9 million in the fourth quarter.
Subsequently, Enveric raised about $1.5 million in a registered direct offering in January 2026 and approximately $1.45 million via an at-the-market offering in February 2026. Operationally, the company advanced its lead candidate EB-003, a non-hallucinogenic neuroplastogen, by completing pre-IND dose range finding studies, achieving key manufacturing milestones, and receiving FDA feedback allowing streamlined plans for an IND submission ahead of a planned first-in-human Phase 1 trial. Enveric also strengthened its intellectual property around the EVM301 and EVM401 compound series, executed licensing agreements for cannabinoid-COX-2 conjugates, expanded a topical cannabinoid collaboration, and completed a 1-for-12 reverse stock split while relocating its headquarters to Cambridge, Massachusetts.
Enveric Biosciences, Inc. filed an 8-K describing that it has filed a prospectus supplement to register an additional $1,346,000 of shares of its common stock issuable under its existing At The Market Offering Agreement with H.C. Wainwright & Co., LLC.
The Agreement was originally dated April 9, 2025, and Enveric has previously sold an aggregate of $1,853,878.34 of common stock through the sales agent under this arrangement. A legal opinion from Greenberg Traurig, LLP regarding the validity of the newly registered shares is included as Exhibit 5.1, with a related consent in Exhibit 23.1.
Enveric Biosciences entered into a financing that combines a registered direct stock sale with a concurrent private warrant placement. The company sold 328,802 common shares at $4.41 per share for gross proceeds of about $1.5 million and expects net proceeds of roughly $1.25 million after fees and expenses.
Investors in the private placement received Series G and Series H warrants to buy up to 328,802 shares each at an exercise price of $4.16 per share, exercisable immediately, with expirations tied to the effectiveness of a resale registration statement. H.C. Wainwright received cash fees, expense reimbursements and warrants to purchase 23,016 shares at $5.5125 per share for five years.
The company agreed to file a resale registration for the warrant shares within thirty days of closing and included a beneficial ownership cap of 4.99%, or 9.99% at the holder’s election, on warrant exercises. It also agreed not to issue additional equity or equity-linked securities for 15 days after closing, and plans to use the proceeds for product development, working capital and general corporate purposes.
Enveric Biosciences, Inc. filed a current report to let investors know that it has prepared an updated Q1 2026 Investor Presentation. Management plans to post this presentation on the company’s website on or about January 9, 2026 and may use it in future meetings with investors, analysts, lenders, business partners, acquisition candidates, customers, employees, and other interested parties.
The presentation is furnished as Exhibit 99.1 and is also accessible through Enveric’s investor events webpage, although website materials are not part of the report. The company specifies that the Investor Presentation is being “furnished” under Regulation FD rather than “filed,” which means it is not subject to certain Exchange Act liabilities and will only be incorporated into other SEC documents if specifically referenced.
Enveric Biosciences entered into warrant exercise inducement agreements with institutional holders of existing warrants for up to 426,390 shares, reducing the exercise price to $7.05 per share. In return, the company agreed to issue new Series E warrants for 426,390 shares and new Series F warrants for another 426,390 shares, plus placement agent warrants for 29,847 shares. Cash exercises of the existing warrants generated approximately $3.1 million in gross proceeds, which Enveric plans to use for product development, working capital and general corporate purposes.
The new warrants are immediately exercisable at $7.05 per share and will expire five years after the resale registration becomes effective for the Series E warrants and eighteen months after effectiveness for the Series F warrants. They include anti-dilution adjustments and caps that generally limit any holder to 4.99% ownership, or 9.99% with advance notice. Enveric also agreed to register the resale of the new warrant shares, temporarily restrict other equity issuances and registration filings, and avoid variable-rate transactions for one year after closing.
Enveric Biosciences reported the results of a Special Meeting of Stockholders held on December 11, 2025. A total of 2,502,133 shares of common stock were represented, equal to 40.23% of shares entitled to vote, which was enough for a quorum.
Stockholders approved an “Issuance Proposal” authorizing, for Nasdaq Listing Rule 5635(d) purposes, the issuance of common shares underlying certain warrants issued under prior inducement and engagement letters. They also approved a “Reverse Stock Split Proposal,” allowing the board, at its discretion, to implement a reverse split of issued and outstanding common stock at a ratio between 1-for-5 and 1-for-15.
In addition, stockholders approved an “Authorized Stock Increase Proposal” to amend the charter to increase authorized common shares from 100,000,000 to 5,000,000,000. Because all key proposals were approved, the adjournment proposal was moot, and no other matters were brought to a vote.
Enveric Biosciences (ENVB) announced it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2). Nasdaq notified the company on November 12, 2025, that the issue is resolved and the matter is now closed. This confirms ENVB’s continued listing on The Nasdaq Capital Market.
Enveric Biosciences filed an 8-K detailing Nasdaq compliance updates and a reverse stock split. The company reported gross proceeds of approximately $2.2 million from cash exercises of existing warrants under an inducement offer, and stated that, as a result, it believes stockholders’ equity now exceeds the $2.5 million requirement under Nasdaq Listing Rule 5550(b)(1). Nasdaq will continue to monitor compliance.
On October 22, 2025, Enveric received a Nasdaq notice that its common stock failed the $1.00 minimum bid price requirement for 30 consecutive trading days and is not eligible for the standard compliance period due to a prior reverse split. The company will request a hearing, which stays any suspension pending the process. To address bid price, the board approved a 1-for-12 reverse stock split effective October 28, 2025, reducing outstanding shares from 6,219,568 to approximately 518,297, with no fractional shares issued and authorized shares unchanged at 100,000,000.
Enveric Biosciences entered into warrant exercise inducement agreements with institutional investors, leading them to exercise existing Series A and B warrants at a reduced price of $0.915 per share instead of $3.00. This generated approximately $2.2 million in gross cash proceeds before fees. In return, Enveric issued new Series C and Series D warrants covering up to 4,849,996 shares of common stock in total, plus placement agent warrants for up to 169,750 shares, all with specified exercise periods tied to future stockholder approval. The company plans to use the net proceeds for working capital and general corporate purposes and will seek to register the resale of shares underlying the new warrants.
Enveric Biosciences, Inc. filed a current report to announce an operational change and related communication. Effective September 2, 2025, the company changed its principal executive office address to 245 First Street, Riverview II, 18th Floor, Cambridge, MA 02142. The company also furnished a press release as an exhibit, which discusses the same matters under Regulation FD. Enveric’s common stock, with a par value of $0.01 per share, continues to trade on The Nasdaq Stock Market under the symbol ENVB.
Enveric Biosciences, Inc. filed a current report to let investors know that it has prepared an Investor Presentation for Q3 2025. Management plans to post these materials on the company’s website and may use them in discussions with current and potential investors, analysts, lenders, business partners, acquisition candidates, customers, and employees.
The Investor Presentation is furnished as Exhibit 99.1 to this report and is also accessible through Enveric’s investor relations webpage. The company specifies that this information is being “furnished” under Regulation FD, meaning it is not treated as filed for liability purposes under the Exchange Act unless specifically incorporated into another filing.
Enveric Biosciences, Inc. reported that Nasdaq has notified the company it is not meeting the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires at least $2,500,000 of stockholders’ equity, while Enveric’s Form 10-Q for the period ended June 30, 2025, reported stockholders’ equity of $2,184,769.
The company also does not meet Nasdaq’s alternative standards based on market value of listed securities or net income from continuing operations. Enveric has 45 calendar days, until October 10, 2025, to submit a plan to regain compliance, and Nasdaq may grant up to a 180-day extension if the plan is accepted. If the plan is not accepted, Enveric could appeal the determination to a Nasdaq Hearings Panel, and the company states that it intends to submit a compliance plan and monitor its stockholders’ equity.
Enveric Biosciences furnished a press release providing a corporate update and announcing financial results for the quarter ended June 30, 2025, which is attached as Exhibit 99.1 to this Current Report on Form 8-K. The filing also includes a machine-readable Interactive XBRL cover page (Exhibit 104). The Form states the press release and related information are furnished, not filed, and therefore are not subject to Section 18 liability or automatically incorporated by reference into future registration statements except by specific reference.
No numerical financial figures or earnings tables are included in the body of the Form 8-K itself; the substantive financial results are contained in the furnished press release. The filing is signed by Chief Executive Officer Joseph Tucker, Ph.D.